MAPT and Alzheimer disease: Although 18F-THK523 imaging failed in visualizing the tau deposits clearly in patients with AD [105], 18F-THK5105 and 18F-THK5117 demonstrated a robust difference between patients with AD and healthy control subjects in brain regions known to contain high density of tau deposits (Figure 5).